Peptide Protocol
Peptide Protocol
App Store

KPV: the complete guide

KPV is the C-terminal tripeptide (Lys-Pro-Val) of alpha-melanocyte-stimulating hormone (α-MSH). Research focuses on its anti-inflammatory properties in gastrointestinal, skin, and systemic inflammation models.

Written by Peptide Protocol Editorial Medically reviewed per our review process Last reviewed
ClassAnti-inflammatory tripeptide (α-MSH 11-13)
Half-lifeApproximately 1–2 hours
Typical dose500–1000 mcg daily (subcutaneous); oral protocols also used
CategoryAnti-inflammatory / immune
Research useGI inflammation research, skin inflammation, systemic low-grade inflammation
FDA statusNot FDA approved. Research use only in the US.

How KPV works

KPV binds intracellular targets and melanocortin receptors at low affinity, downregulating NF-κB and pro-inflammatory cytokine production. Evidence is strongest in IBD and colitis animal models.

Typical KPV dosage

Commonly reported research ranges: 500–1000 mcg daily (subcutaneous); oral protocols also used.

Dose should always be individualized. Factors that influence it include bodyweight, research goal, tolerance, and specific compound batch. The information below is educational, not a prescription.

How to reconstitute KPV

A widely used reconstitution for a 5 mg vial is 2 ml of bacteriostatic water. With a typical 500 mcg dose this works out to the unit count shown in the calculator below.

Open the KPV reconstitution calculator →

Pre-filled with the common 5 mg + 2 ml ratio. Adjust for your own vial.

Half-life and administration frequency

Approximately 1–2 hours.

This half-life informs how often KPV is typically dosed. Shorter half-lives usually mean more frequent dosing to maintain plasma levels; longer half-lives allow daily, weekly, or less-frequent administration depending on the compound.

Reported side effects

This list reflects effects reported in available literature or user logs. It is not exhaustive. Adverse reactions should be discussed with a qualified clinician.

Common KPV stacks

Storage and handling

Lyophilized: refrigerated. Reconstituted: refrigerated, use within 28 days.

FDA and regulatory status

Not FDA approved. Research use only in the US.

KPV clinical trials and evidence

For clinical-trial and primary-literature context, start with the sources below. We prioritize official drug labels, ClinicalTrials.gov records, and PubMed-indexed literature when available.

Track your KPV protocol on iPhone

Peptide Protocol logs every dose, calculates reconstitution for you, and keeps your full protocol on one calm screen.

See the app →

Frequently asked questions

What is KPV?

KPV is the C-terminal tripeptide (Lys-Pro-Val) of alpha-melanocyte-stimulating hormone (α-MSH). Research focuses on its anti-inflammatory properties in gastrointestinal, skin, and systemic inflammation models.

How does KPV work?

KPV binds intracellular targets and melanocortin receptors at low affinity, downregulating NF-κB and pro-inflammatory cytokine production. Evidence is strongest in IBD and colitis animal models.

What is a typical KPV dose?

Commonly reported ranges are 500–1000 mcg daily (subcutaneous); oral protocols also used. This is research information, not a recommendation — dosing should be individualized under clinical guidance.

What is the half-life of KPV?

Approximately 1–2 hours. This influences how often it is administered.

How do you reconstitute KPV?

A common approach is to add 2 ml of bacteriostatic water to a 5 mg vial. Use the reconstitution calculator for exact unit counts.

What are the side effects of KPV?

Injection-site reactions; Limited human safety data; No well-characterized serious adverse events in published animal data.

Is KPV FDA approved?

Not FDA approved. Research use only in the US.

Are there clinical trials for KPV?

Registered or published clinical-trial sources for KPV are listed in the references section below. Evidence depth varies widely by compound, so check the cited trial registries and primary literature before relying on any claim.

References

  1. KPV tripeptide literatureNational Library of Medicine. Primary research on KPV anti-inflammatory activity
  2. Dalmasso et al. — KPV in colitis modelsPubMed. Preclinical evidence in IBD/colitis models
  3. α-MSH and KPV derivatives trial recordsClinicalTrials.gov. Related clinical research on α-MSH derivatives

Sources listed above were used to verify the claims on this page. See our editorial policy for how we source information.

Educational use only. Peptide Protocol is an informational tool. Nothing on this page constitutes medical advice. Many peptides are prescription-only or restricted in your jurisdiction. Always consult a licensed healthcare professional before injecting any compound.